ORIC PHARMACEUTICALS INC.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | ORIC |
| ISIN: |
ORIC PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
ORIC PHARMACEUTICALS INC. - More news...
ORIC PHARMACEUTICALS INC. - More news...
- 03/25/2025 - 20:30 ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
- 03/07/2025 - 21:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 02/25/2025 - 21:15 ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
- 02/18/2025 - 21:05 ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
- 02/07/2025 - 21:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 01/27/2025 - 21:15 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- 01/13/2025 - 13:05 ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
- 01/13/2025 - 13:00 ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
- 01/06/2025 - 21:15 ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- 01/03/2025 - 21:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 11/25/2024 - 21:15 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- 11/12/2024 - 21:05 ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
- 11/04/2024 - 21:15 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- 11/01/2024 - 20:30 ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 10/23/2024 - 11:00 ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 10/09/2024 - 20:15 ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 10/04/2024 - 20:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 09/06/2024 - 20:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 08/26/2024 - 20:05 ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- 08/12/2024 - 20:05 ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
- 08/05/2024 - 20:15 ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
- 08/02/2024 - 20:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 07/16/2024 - 20:59 ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
- 07/05/2024 - 20:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 06/07/2024 - 20:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 05/29/2024 - 20:30 ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- 05/06/2024 - 20:05 ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
- 05/03/2024 - 20:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 04/15/2024 - 20:15 ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
- 04/08/2024 - 12:00 ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
